Smad7 is an inhibitor of the transforming growth factor-β-activated signaling pathway. Under welloxygenated conditions, Smad7 is a potent inhibitor of carcinoma cell invasion. Paradoxically, however, the expression of Smad7 is upregulated across several cancers and may promote cancer progression. Hypoxia, which is frequently met in solid tumors, is an enhancer of carcinoma cell invasion and cancer progression. Here, we report that hypoxia activates the expression of Smad7 in a hypoxia-inducible factor-and von HippelLindau protein-dependent manner. As expected, in normoxia, the forced expression of Smad7 inhibited carcinoma cell invasion. In contrast with the normoxic condition, the inhibitory effect of Smad7 was lost under hypoxia. The block in carcinoma cell invasion by forced expression of Smad7 was released by hypoxia in two invasive carcinoma cell lines. Moreover, the noninvasive HaCaT keratinocytes become invasive upon simultaneous hypoxia and transforming growth factor-β stimulus. The hypoxia-activated invasion was attenuated by inhibiting Smad7 expression by short interfering RNA. Finally, the increased Smad7 expression in human carcinomas correlated with hypoxic gene expression. The data provide evidence that hypoxia could convert Smad7 function from an invasion inhibitor into an activator of invasion. Furthermore, they might shed light as to why increased Smad7 expression is detected in cancers.
Introduction
The transforming growth factor (TGF-β) family members include at least three TGF-βs, bone morphogenetic proteins (BMP), activins, and inhibins (1, 2) . In epithelial cells, TGF-β is a homeostasis-guarding factor that restricts the growth of normal epithelium and benign neoplasms. However, in more advanced malignancies of epithelial origin, the TGF-β function is converted to promote tumor growth, invasion, and metastasis. In fact, several studies indicate TGF-β as a potent metastasis inducer (3) (4) (5) . The cellular responses to TGF-β are mediated by R-Smads (e.g., Smad2 and Smad3), which are activated by serine phosphorylation at their COOHterminal ends by the TGF-β receptors (TGFβR type I and type II; refs. [6] [7] [8] . The active R-Smads form a complex with Smad4 that binds to Smad-responsive DNA elementactivating target genes, such as cell cycle inhibitors p21, p15, and a TGF-β signaling inhibitor Smad7.
Smad7 is an inhibitory Smad that is a crucial regulator of TGF-β signaling (9, 10) . Smad7 can inhibit all of the R-Smadactivated transcription. The inhibition occurs either by substituting R-Smads from the receptor or by targeting the R-Smads for degradation. Smad7 may also recruit phosphatases to inactivate the receptor (9, 11, 12) . Smad7 is expressed across several cell types including endothelial and epithelial cells. In epithelial cells, Smad7 has been shown to block most of the TGF-β1-induced Smad2/3-mediated transcription (10, 13) . In endothelial cells, Smad7 regulates the duration of the TGF-β signal and the outcome of different TGFβRI (ALK1 and ALK5) signals (14) . In newly forming vessels, Smad7 may cause deformed vasculature (15) . In line with the functions in vasculogenesis, Smad7 has been detected to be upregulated by hypoxia in endothelial cells (16) .
During cancer progression, the role of Smad7 is somewhat contradictory. Ectopic expression of Smad7 inhibits invasion and cancer progression both in vitro and in vivo (17) (18) (19) . On the other hand, Smad7 has been linked to malignant transformation with ras oncogene (20) and increased tumorigenicity (21) . These Smad7-linked effects are early events in the development of malignancy. Indeed, several animal and clinical studies indicate that Smad7 is beneficial for tumor growth and Smad7 expression is increased across a number of cancers such as renal carcinomas (22, 23) , squamous cell carcinomas of the head and neck region (HNSCC; refs. [24] [25] [26] [27] , pancreatic, and colorectal cancers. Moreover, a number of animal studies have shown Smad7 to be tumorigenic (28) (29) (30) (31) . In gastric and colorectal carcinomas, Smad7 expression is regarded as a poor prognosis factor, whereas Smad4 expression indicated a better prognosis (28, 32) . In HNSCC, Smad7 expression has been shown to be higher in metastasis compared with the primary tumor (26, 33) .
The majority of solid malignant tumors are hypoxic. Hypoxia is also regarded as a marker of aggressive cancer, and it correlates with resistance to treatment and poor prognosis (34) . Hypoxia activates ∼100 genes through the hypoxiainducible factors (HIF-1 and HIF-2; ref. 35 ) that regulate the survival, angiogenesis, and energy metabolism of tissues. HIF activity is regulated in an oxygen-dependent manner by HIF prolyl hydroxylases (36) . The prolyl hydroxylases target the HIF-α subunits for proteasomal degradation via the von Hippel-Lindau protein (pVHL) under normoxia. Under hypoxia, the degradation is attenuated and HIF-α is stabilized (37) . HIF-1α is expressed in most human cancers, and the expression correlates with poor patient prognosis.
Here, we report that Smad7 is activated by hypoxia in a HIF-and pVHL-dependent manner leading to the inhibition of TGF-β signaling. As reported previously, in normoxia, Smad7 effectively inhibits the invasion of HNSCC and HeLa cells. However, exposing the cells to hypoxia released the inhibitory effect of Smad7 on invasion. In fact, under hypoxia, the expression of Smad7 increased the invasiveness of otherwise poorly invasive HaCaT keratinocytes. Accordingly, in carcinomas, the upregulation of Smad7 is associated with hypoxia.
Materials and Methods
Cell culture, transfection, and viral infections HeLa, HepG2, and HaCaT cells were cultured in DMEM (Sigma-Aldrich) containing 10% FCS, 20 units/mL of penicillin, 50 μg/mL of streptomycin, 2 mmol/L of L-glutamine, and RCC+ pVHL cells with 250 μg/mL of G-418 (Sigma-Aldrich). Human umbilical vein endothelial cells (HUVEC) were provided by Dr. E. Iivanainen (Department of Medical Biochemistry, Turku University, Finland) and grown in RPMI medium (Sigma-Aldrich) with 10% human AB serum (Finnish Red Cross), 1.4 units/mL of heparin, and 20 μg/mL of endothelial cell growth factor. Transfections were performed with Effectene (Qiagen) following the protocols of the manufacturer with 500 ng of plasmid. For hypoxia (1% O 2 , 5% CO 2 , 90% moisture), Invivo2 workstation (Ruskinn Technologies) was used. Oxygen was replaced with 99.5% N 2 (AGA, Finland). Cobalt chloride (CoCl 2 ) was used at 100 μmol/L CoCl 2 (SigmaAldrich). Growth factor-treated cells were grown in minimal serum (CMS; fetal bovine serum passed through 2% charcoal/ dextran; Hyclone) prior to TGF-β1 or BMP2 supplementation (Promocell) at 5 ng/mL. Adenovirus-exposed cells were incubated for 4 hours at +37°C. For short interfering RNA (siRNA) experiments, 21-mer oligonucleotides were used. siSmad7#1 (5′-AGGUCACCACCAUCCCCACdTdT-3′; Eurogentec), siSmad7#2 (5′-GGACGCUGUUGGUACACAAdTdT-3′; MWG Biotech), and HIF siRNAs (38) at 60 nmol/L and transfected with Trans-IT-TKO (Mirus) following the protocols of the manufacturer. SB431542 (Sigma) was used at 5 μmol/L.
Protein and mRNA analysis
RNA was extracted with RNeasy mini kit (Qiagen). Proteins were run on SDS-PAGE or Criterion precast gels (Bio-Rad) and transferred on polyvinylidene difluoride membranes (Millipore). Western blots were performed in 5% bovine serum albumin in TBS 0.1% Tween 20 with primary antibodies: P-Smad3 (R&D Systems) at 1:2,500, Smad7 (Imgenex, Abcam, Abnova, R&D Systems, or Upstate) at 1:2,500, HIF-1α (Transduction Laboratories) at 1:2,500 and AC-40 actin (SigmaAldrich) at 1:5,000. Anti-mouse horseradish peroxidase and anti-rabbit horseradish peroxidase (DAKO) were used at 1:10,000. For quantitative reverse transcription-PCR (QRT-PCR; TaqMan) cDNA was prepared with Moloney murine leukemia virus reverse transcriptase (H − ; Promega) and nucleotide triphosphate mix (Fermentas) at 0.5 mmol/L and analyzed according to the protocols of the manufacturer (Applied Biosystems). TaqMan probes and primers (Eurogentec) are listed in Supplementary Table S1 . The expressions were normalized against EF-1α. For microarray studies, a cDNA in-house microarray containing 4,000 genes was used. For database studies, Oncomine was used (39) .
Matrigel invasion assay
Invasion assays were performed on 24-well plates using ThinCerts with 8 μm pore (Greiner Bio-One) and Matrigel (BD Biosciences). Matrigel was diluted in serum-free DMEM (Sigma) to 2 mg/mL and supplemented with TGF-β and/or the TGF-β receptor inhibitor SB431542. Twenty thousand cells were plated in each insert. The outer well was filled with DMEM, and TGF-β was added to the inner and outer wells. For siRNA experiments, the cells were transferred to the Matrigel 24 hours after transfection. The adenoviral transductions were done 6 hours prior to transfer on Matrigel. After 24 hours, the membranes were stained with Hoechst 33342 and counted using a Lumar stereofluorescence microscope (Zeiss).
Luciferase assays
Cells were cotransfected with Smad7 promoter-firefly luciferase or CAGA12-firefly luciferase together with ubiquitin promoter-driven renilla luciferase and the experimentdependent expression constructs. siRNA transfections were performed 1 day prior to reporter construct transfection. The transfected cells were seeded on 96-well plates for treatment measurements. The signals were measured with Dual Glow luciferase assay system (Promega) and Victor 2 plate reader (Perkin-Elmer). TGF-β was applied 3 hours prior to luciferase activity measurement.
Patient samples
Tumor samples were collected, after informed consent, from surgically removed oral and oropharyngeal HNSCC in Turku University Central Hospital, Finland. The use of tumor samples was approved by the National Authority for Medicolegal Affairs. Normal tissue samples were collected from patients undergoing uvulo-palato-pharyngoplasty. Samples were from both genders, and the patients' ages ranged from 29 to 87 years. The patient material has been described in detail elsewhere (40) .
Results

Smad7 gene is induced by hypoxia across several cell types
Hypoxia induces TGF-β1 and TGF-β3 expression (41, 42) . To investigate whether the expression of the downstream components in the TGF-β pathway are affected by hypoxia, we used microarray analysis of hepatocellular carcinoma (HepG2) cells exposed to 16 hours of hypoxia (1% O 2 ) or normoxia (21% O 2 ). Among the known hypoxia-activated genes, such as Glut-1, the TGF-β signaling inhibitor Smad7 was strongly induced by hypoxia. Other Smad genes (Smads1-4) did not show any response to hypoxia (Fig. 1A) . For validation, we performed QRT-PCR analysis from three other cell lines, a carcinoma cell line (HeLa), an immortalized keratinocyte cell line (HaCaT), and a primary endothelial cell line (HUVEC). Smad7 was robustly upregulated both by hypoxia and by chemical hypoxia mimetics (CoCl 2 ) at two different time points (6 and 16 hours). The upregulation of Smad7 was comparable with that of hypoxic marker gene Glut-1 (Fig. 1B) . The hypoxia-activated Smad7 was mainly expressed in the cytoplasm ( Supplementary Fig. S1 ).
Besides cells of epithelial origin, the primary HUVECs showed a strong induction of Smad7 both in hypoxia and chemical hypoxia (Fig. 1C) . To further validate our finding, we performed an in silico analysis (Oncomine) for Smad7 expression in endothelial cells. In line with our results, at least one study performed in coronary artery endothelial cells showed upregulation of Smad7 in hypoxia (2% O 2 ) and further upregulation in anoxia (0% O 2 ; Fig. 1D ; ref. 16 ).
The hypoxic Smad7 gene activation is HIF-and pVHL-dependent
To address the question of whether Smad7 was under the control of the HIF pathway, we first forced HIF to be expressed under normoxia in HeLa cells and performed QRT-PCR analysis for Smad7 ( Fig. 2A) . Both HIF-1α and HIF-2α increased Smad7 mRNA; however, a greater increase was seen with HIF-1α. The Smad7 upregulation correlated with Glut-1, which responds more to HIF-1α than to HIF-2α (43) . We next depleted HIF-1α using previously validated siRNA (38) and exposed the cells to hypoxia. In accordance with the forced HIF expression under normoxia, the depletion of HIF-1α resulted in almost complete ablation of the hypoxic Smad7 upregulation. Again, Glut-1 expression was attenuated comparably to Smad7 (Fig. 2B) .
The proximal promoter of Smad7 was found to contain a hypoxia-responsive element in close proximity with the Smad-binding element ( Supplementary Fig. S2A ). To analyze the functionality of the hypoxia-responsive element, we used a Smad7 promoter-driven luciferase reporter (Smad7-Luc; ref. 44 ) that was transfected into HeLa cells. Upon hypoxia, Smad7-Luc was activated 2-fold ( Supplementary Fig. S2B ). We further used HIF siRNA in hypoxia ( Supplementary  Fig. S2B ) and a constitutively active HIF-1α under normoxia ( Supplementary Fig. S2C ) to address whether the activation was HIF-dependent. Supporting the activation of Smad7 by HIF, reporter gene activity was reduced by HIF-1α siRNA, and vice versa, activated by forced HIF-1α expression. In accordance, the inhibition of TGF-βRI by SB431542 allowed the activation of Smad7-luc under hypoxia, implying that the promoter is at least partially directly driven by HIF (Supplementary Fig. S2D ). Supporting this, under SB431542 exposure, the Smad7 mRNA expression was also activated by hypoxia ( Supplementary Fig. S2E ). Taken together, the data imply that the hypoxic and TGF-β pathways cooperate in the regulation of Smad7 expression.
Deletion of pVHL constitutively activates HIF-1α expression. To confirm the dependency of the hypoxic Smad7 activation by the HIF pathway, we used a VHL-deficient renal clear cell carcinoma cell line (RCC4−) in parallel with a rescued pVHL-transfected cell line (RCC4+). As expected from the previous results, both Glut-1 and Smad7 genes were overexpressed in RCC4− cells as compared with the RCC4+ cells in normoxic conditions (Fig. 2C ). In line with this, neither hypoxia nor CoCl 2 were able to induce Smad7 or Glut1 mRNA in RCC4− cells. However, the hypoxia-dependent induction of both genes was restored in RCC4+ cells (Supplementary Fig. S3 ).
Finally, we used Oncomine database searches for Smad7 expression in normal renal epithelial cells as well as for renal clear carcinomas. Roughly 70% of the sporadic renal clear cell carcinomas pose inactivated pVHL and thus, have HIF-activated genes constantly upregulated (45) . Normal renal cells revealed the induction of Smad7 in response to Fig. 2D; ref. 16 ). However, a study comparing samples from normal kidney cells to RCC patient samples showed the upregulation of Smad7 in RCCs over the healthy kidney samples ( Fig. 2D;  refs. 22, 23) . These results show that hypoxic Smad7 induction is dependent on the activation of the HIF pathway and that Smad7 mRNA is overexpressed in pVHL-deficient cancer cells as well as in sporadic renal carcinomas.
Hypoxia-activated Smad7 inhibits R-Smad phosphorylation
Smad7 is an autoinhibitor of TGF-β signaling with a main function of inhibiting R-Smad phosphorylation. Functional Smad7 should cause a decrease in R-Smad phosphorylation at the COOH terminus. To study whether the hypoxia-activated Smad7 blocks R-Smad phosphorylation, we exposed HaCaT cells to TGF-β both in hypoxic and normoxic conditions and analyzed Smad3 phosphorylation by Western blot analysis. Under normoxia, TGF-β induced Smad3 phosphorylation (Fig. 3A, lanes 2-5) . In accordance with the hypoxic Smad7 upregulation, under hypoxia, Smad3 phosphorylation was inhibited (Fig. 3A, lanes 7-10) . We further correlated the phosphorylated Smad3 (p-Smad3) level to total Smad3 (t-Smad3) as well as total Smad3 to β-actin (Fig. 3B) . The data implied that hypoxia inhibits Smad3 COOH-terminal phosphorylation rather than activating Smad3 degradation. In line with this, CoCl 2 blocked Smad3 phosphorylation but had no effect on the total Smad3 levels ( Supplementary Fig. S4A ).
We next asked if the hypoxic block in Smad3 phosphorylation was due to elevated Smad7. We used two different siRNA oligonucleotides against Smad7. The efficacy of the Smad7 siRNAs was tested in HeLa cells by Smad7 and Glut-1 mRNA expression analysis by QRT-PCR and the inhibition of adenoviral Smad7 expression ( Supplementary   Fig. S4B and C) . Both Smad7 siRNAs efficiently attenuated Smad7 expression without having a marked effect on Glut-1, and furthermore, also suppressed the forced Smad7 expression. Next, HeLa cells were transfected with nontarget or Smad7 siRNAs and exposed to TGF-β either in normoxia or hypoxia. As expected, the nontarget siRNA-treated cells showed an induction of Smad3 phosphorylation in normoxia whereas hypoxia prevented the TGF-β-induced phosphorylation. However, both Smad7 siRNAs rescued the effect of hypoxia on Smad3 phosphorylation (Fig. 3C) . Similar to hypoxia, under chemical hypoxia (CoCl 2 ), both Smad7 siRNAs rescued Smad3 phosphorylation. (Fig. 3D) . Moreover, the TGF-β-induced activation of P15 expression that was attenuated by hypoxia (46) , was reversed by the Smad7 siRNAs (Supplementary Fig. S5A ), whereas the expression of hypoxia-activated carbonic anhydrase 9 (CAIX) was not affected ( Supplementary  Fig. S5B ). In line with this, the hypoxic activity of the TGF-β-driven CAGA luciferase was increased by Smad7 depletion (Supplementary Fig. S5C ). These data indicate that hypoxiaactivated Smad7 is able to inhibit TGF-β signaling.
Hypoxia reverts the inhibitory function of Smad7 on invasion
Smad7 is a well-characterized inhibitor of TGF-β-induced carcinoma cell invasion (17) (18) (19) , but paradoxically, is overexpressed in many cancers. We studied the effect of the hypoxic Smad7 expression on cell invasion in naturally invasive HNSCC cell line, UT-SCC-7 (17) , and compared that with virtually noninvasive HaCaT cells using a standard Matrigel invasion assay in the presence of TGF-β. As reported previously, UT-SCC-7 cells were invasive in normoxia and this was not affected by hypoxia (Fig. 4A) . However, HaCaT cells that were poorly invasive in normoxia showed, in striking contrast with UT-SCC-7, strongly enhanced cell invasion Figure 3 . Hypoxic Smad7 upregulation inhibits TGF-β signaling. A, phosphospecific Smad3 (p-Smad3) and total Smad3 (t-Smad3) Western blot analysis demonstrating induction of Smad3 phosphorylation by TGF-β in HaCaT cells under normoxia. In hypoxia, Smad3 phosphorylation is inhibited. B, quantification of p-Smad3 and t-Smad3 levels under the indicated conditions. p-Smad3 levels were correlated to t-Smad3 and t-Smad3 to β-actin. C, Smad3 phosphorylation in HeLa cells exposed to nontarget or two independent Smad7 siRNAs (S7#1 and S7#2). D, HeLa cells exposed to the indicated siRNA followed by exposure to TGF-β and CoCl 2 . C and D, all samples were run on one gel and the white bars indicate removal of unnecessary information.
through Matrigel under hypoxic conditions (Fig. 4A and B) . The data suggested that the hypoxic Smad7 cannot inhibit carcinoma cell invasion. Moreover, the results led us to hypothesize that the hypoxic Smad7 expression might in fact promote the invasiveness of otherwise poorly invasive cells. Indeed, HaCaT cells exposed to Smad7 siRNA showed reduced cell invasion in hypoxia. The inhibition of HaCaT cell invasion in hypoxia was seen by the two independent Smad7 siRNAs ( Fig. 4B and C) , implying that Smad7 supports cell invasion under hypoxia. Interestingly, an intact expression of HIF-1α was also required for full invasion as judged by attenuated invasion under HIF-1α siRNA exposure ( Fig. 4B and  C; Supplementary Fig. S6A-D) .
We next studied the function of forced Smad7 expression on cell invasion by using adenovirus-based gene transfer in two strongly invasive cell lines, HeLa and UT-SCC-7, and compared the effects of hypoxia to normoxia. Previous studies have shown that adenovirally expressed Smad7 decreases the invasion capacity of carcinoma cells (17) . In line with these reports, in contrast with control adenoviral expression of Lac-Z (Ad-LacZ), the expression of Smad7 (Ad-Smad7) strongly inhibited the invasion of UT-SCC-7 cells in normoxic conditions (Fig. 5A and B) . Under normoxia, the Ad-Smad7-induced inhibition on cell invasion was robust. Strikingly, in contrast with the normoxic situation, the inhibitory effect of Smad7 on invasion was almost completely lost under hypoxia (Fig. 5A) . When comparing cell invasion under normoxic and hypoxic Smad7 expression to control, Smad7 was seen to reduce cell invasion by 60% (mean effect) under normoxia but was not able to reduce the invasion under hypoxia (Fig. 5B) . Similarly to the UT-SCC-7 cells, in the strongly invasive HeLa cells, the forced Smad7 expression potently inhibited cell invasion under normoxia. Again, the Smad7-induced inhibition on invasion was completely lost under hypoxia (Fig. 5C and  D) . It needs to be noted that adenoviral infection, as such, did not affect invasion as the Ad-LacZ-infected cells were The hypoxia-activated HaCaT cell invasion is lost when exposed to either of the Smad7 siRNA (S7#1 and S7#2) or HIF-1α siRNA (*, P < 0.05; **, P < 0.01; ***, P < 0.001).
invasive both in normoxia and hypoxia. Also, the adenoviral expression of Smad7 was not affected by hypoxia (data not shown). Supporting the effect of hypoxia on Smad7-induced invasion, the attenuation of HIF-1α reduced the hypoxic cell invasion under forced Smad7 expression in both UT-SCC7 and HeLa cells. Moreover, under hypoxia and forced Smad7 expression, the inhibition of TGF-βRI did not block cell invasion ( Supplementary Fig. S6 ). These results imply that hypoxia reverses the inhibitory function of Smad7 on invasion. In fact, the data argue that hypoxia might use Smad7 to promote invasion in cells that are primarily poorly invasive.
Smad7 is upregulated in human HNSCC
Smad7 has been shown to be overexpressed in human tumors, which are also often hypoxic. Based on the finding that hypoxia activates Smad7 in an HIF-dependent manner, we asked whether Smad7 expression correlates with hypoxia in human tumors. First, we analyzed HNSCC samples and healthy tissue (uvula) samples with QRT-PCR. Smad7, Glut-1, lactate dehydrogenase-A (LDH-A), vascular endothelial growth factor-A (VEGF-A), and Smad4 expression were studied from 13 control samples and 28 HNSCC samples. As expected, the hypoxic marker gene Glut-1 as well as LDH-A and VEGF-A were upregulated in HNSCC samples. Also, Smad7 showed significant upregulation in cancer samples, whereas Smad4 did not show changes in the expression between control and cancer ( Fig. 6A; Supplementary Fig. S7 ). Supporting our data, studies in the Oncomine database showed similar results for HNSCC. In the majority of HNSCC studies, the Smad7 gene is clearly upregulated in cancer samples (Fig. 6B) . Two independent example studies show statistically significant Smad7 overexpression, whereas two studies showed a trend towards Smad7 overexpression in HNSCC ( Fig. 6B; refs. [24] [25] [26] [27] . We next analyzed the association between hypoxia and Smad7. Noticeably, Smad7 expression significantly correlated with the HIF downstream gene Glut-1 in HNSCC (Fig. 6C) . Similarly to Glut-1, both LDH-A and VEGF-A correlated with Smad7 expression in the cancer samples (correlation coefficient, 0.4 for both genes; P < 0.02 and 0.03, respectively). Finally, because cell invasion is required for metastasis formation, we analyzed the Oncomine database for analyses studying the difference between primary tumors and metastases. At least two studies revealed increased Smad7 in metastatic tumors over the primary tumor ( Fig. 6D ; refs. 26, 27) , suggesting that Smad7 overexpression in cancer could be beneficial for metastasis.
Discussion
Smad7 has been shown to inhibit invasion in malignant cells of epithelial origin under normoxia (17, 18, 21, 47) . Somewhat contradictory to this is that Smad7 is known to be upregulated in several carcinomas (28) (29) (30) (31) (32) . Moreover, targeted overexpression of Smad7 has been reported to promote tumor growth, supporting a beneficial rather than inhibitory role in cancer progression (20, 21, 28, 29, 31, 48, 49) . Here, we confirm the inhibitory effect of Smad7 on invasion under normoxic conditions and show upregulation of Smad7 in HNSCC. Importantly, we show that Smad7 is upregulated by hypoxia and that under hypoxia, the inhibitory effect of Smad7 on invasion was abolished. In fact, under hypoxic conditions, Smad7 might enhance invasion as shown by our data on HaCaT invasion. As hypoxia is common in tumors and is a known activator of invasion, the finding offers a potential explanation as to why Smad7 upregulation could be beneficial for cancer progression.
The hypoxic upregulation of Smad7 was seen to occur across carcinoma cells as well as immortalized and primary cells. We showed that hypoxic Smad7 activation was due to HIF-and pVHL-dependent mechanisms and that Smad7 is a transcriptional target of HIF. This also implied that Smad7 overexpression is a common feature of a majority of sporadic and VHL syndrome-associated RCCs. To study the functionality of the hypoxia-activated Smad7, we analyzed its ability to inhibit TGF-β signaling by analyzing R-Smad (Smad3) COOHterminal phosphorylation. As expected, cells treated with TGF-β in normoxia showed induction in R-Smad phosphorylation that was strongly attenuated in hypoxia. Hypoxia is a known inhibitor of cell proliferation and protein production. In some experiments, this was also reflected as a reduced total Smad3 level. However, this was seen only concomitantly with similarly reduced β-actin levels, and comparing total Smad3 and the phosphorylated Smad3 with each other or β-actin showed that the phosphorylated form rather than total Smad3 was reduced in hypoxia. This was further supported by experiments with chemically induced hypoxia with no reduction in the total Smad3 level. Indeed, two independent Smad7-specific siRNA oligonucleotides rescued the hypoxic inhibition in Smad3 phosphorylation without affecting total Smad3 levels. Similarly, the inhibition in Smad3 phosphorylation brought about by chemical hypoxia was reversed by attenuating Smad7 expression. These experiments confirmed that the hypoxiaactivated Smad7 is functional and is able to block the TGF-β signaling at the level of R-Smad COOH-terminal phosphorylation.
TGF-β regulates the migration, proliferation, and growth rate of normal epithelial cells. In contrast with normal cells, however, carcinoma cells are known to escape the growth-regulating effects of TGF-β and might use TGF-β as a metastasis-supporting factor (3) (4) (5) . In line with this, several carcinoma cell lines such as HeLa and the UT-SCC-7 used in this study are strongly invasive under TGF-β exposure. In contrast, HaCaT cells are normally noninvasive without additional oncogenic transformation such as K-Ras. Instead, HaCaT cells respond to TGF-β by attenuating proliferation and accelerating migration. We did not detect a significant effect for hypoxia on the proliferation or migration of TGF-β-treated cells. However, when exposed to simultaneous hypoxia and TGF-β, the noninvasive HaCaT cells become invasive. The invasion was comparable to that seen with either HeLa or UT-SCC-7 cells. In line with the invasion-supporting function of Smad7 in hypoxia, depletion of Smad7 restored the noninvasive phenotype of HaCaT cells. Given the reported function of Smad7 as an inhibitor of cell invasion in TGF-β-treated cells, the hypoxic activation of Smad7 expression was initially difficult to fit in the picture, although it is noticeable that all the work demonstrating the inhibitory effect of Smad7 was performed under normoxia. Also, in our experiments, the inhibitory effect was clearly visible. However, the inhibitory function of Smad7 on invasion was practically completely lost under hypoxia. This was seen in both HeLa and UT-SCC-7 cell lines, in which hypoxia reversed the effect of the virally expressed Smad7.
Mechanistically, a large number of possibilities exist as to how hypoxia might convert the Smad7 function in invasion. First, hypoxia causes posttranslational covalent protein modifications including phosphorylation and hydroxylation. By inducing or inhibiting such modifications, hypoxia could support more permanent R-Smad/Smad7 complex formations and Smad7 might target R-Smads for dephosphorylation and therefore influence Smad-activated transcription. Second, HIF is known to bind Smad3 and this has been reported to modify hypoxic gene activation (50) . Conversely, it is feasible that HIF could alter the R-Smad-Smad4-Smad7 complex binding to DNA. Finally, as hypoxia is known to induce a large set of genes, it is possible that the hypoxia-elicited changes in gene expression could modify TGF-β responses to support rather than inhibit invasion. Whatever the mechanism, we argue that Smad7 plays a crucial role in hypoxia-induced invasion and cancer progression. Conversely, we argue that hypoxia might dramatically change the outcome of TGF-β in cancer progression. Supporting the role of Smad7 in enhancing cancer progression, it is upregulated across multiple cancer types including metastases, in which the expression correlates with hypoxia.
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